A team of researchers at the University of California, Davis, made small tweaks to the molecular structure of lysergic acid diethylamide (LSD) to see if it could be turned into an effective brain-healing treatment for patients that suffer from conditions like schizophrenia — without risking a potentially disastrous acid trip.

As detailed in a new paper published in the journal Proceedings of the National Academy of Sciences last month, the researchers created a new compound called JRT by shifting the position of just two atoms of the psychedelic’s molecular structure.

With the two atoms flipped, the new drug could still stimulate brain cell growth and repair damaged neural connections, while simultaneously minimizing psychedelic effects, in mice.

Researchers have developed an extremely thin, flexible imager that could be useful for noninvasively acquiring images from inside the body. The new technology could one day enable early and precise disease detection, providing critical insights to guide timely and effective treatment.

“As opposed to existing prohibitively large endoscopes made of cameras and optical lenses or bulky fiber optic bundles, our microimager is very compact,” said research team leader Maysam Chamanzar from Carnegie Mellon University. “Much thinner than a typical eyelash, our device is ideal for reaching deep regions of the body without causing significant damage to the tissue.”

In the journal Biomedical Optics Express, the researchers showed that the microimager, which is only 7 microns thick—a tenth of an eyelash diameter—and about 10 mm long, can be used in a mouse brain for structural and functional imaging of brain activity. The width of the thin film imager can be customized based on the desired field of view and resolution.